‘Heart-in-a-box’ better than cooler for heart transplants
en-GBde-DEes-ESfr-FR

‘Heart-in-a-box’ better than cooler for heart transplants


The risk of early heart failure after heart transplantation is lower if the donor heart is stored in a so-called heart-in-a-box instead of in the usual cooler with ice. This is according to a study where researchers at the University of Gothenburg are now presenting the results.
The established way of storing donated hearts before transplantation is to keep them at four degrees in potassium solution in a cooler with ice. Handling is a race against time, where matching, transportation and surgery need to happen within four hours to avoid increasing the risk of complications for the recipient.
Research has shown that transport times of up to nine hours are no longer an obstacle if hypothermic oxygenated machine perfusion (HOPE) or a “heart-in-a-box” is used instead of static cold storage. In the box, the heart is kept at eight degrees and is oxygenated using a pump, a set of tubes, a reservoir and a fluid that is circulated through the resting heart while waiting for the transplantation.
The aim of the current study, published in The Lancet, was to compare the methods, “heart-in-the-box” and cooler, in terms of safety and health outcomes of heart recipients in the first 30 days after transplantation. The study is the first so-called randomized controlled study of its kind.
Eight countries in Europe
The study included 204 adult patients registered for heart transplantation at fifteen different clinics in eight European countries. Half of the participants were randomly assigned to receive hearts handled in a “heart-in-a-box”, while half received hearts from cold static storage according to standard procedures. All hearts came from brain-dead donors.
The results show that heart recipients were significantly less likely to experience heart failure in their new heart if it had been handled in a “heart-in-a-box” before transplantation, compared to standard cold static storage. The risk of severe organ failure, primary graft dysfunction (PGD), was 11% in the heart-in-a-box group and 28% in those whose hearts were stored according to standard practice.
Otherwise, there were no differences in clinical events between the groups during the follow-up period. The researchers will later present analyses of the health outcomes in participants during the first year after heart transplantation.
One of the driving forces of the study is the author Andreas Wallinder, MD, PhD cardiothoracic surgeon and now Medical Director of the Swedish company XVIVO AB, who, together with Stig Steen, Senior Professor at Lund University, developed the used “heart-in-a-box” concept.
“The oxygenation of the heart that takes place in the box is crucial. During normal cold storage and transportation, we have no oxygenation or circulation in the cells, but when we use the box, oxygenated and nutrient-rich fluid is continuously pumped through the heart, which allows the heart to function better and results in fewer complications in the recipient after the transplant,” he says.
More transplants on the horizon
Göran Dellgren is Professor of Transplantation Surgery at Sahlgrenska Academy at the University of Gothenburg, and a cardiothoracic surgeon at Sahlgrenska University Hospital and the Swedish Principal Investigator of the study, responsible for about twenty participants:
“The results represent a breakthrough in transplantation, which could expand the field. Used correctly, the heart-in-a-box can reduce a number of complications that otherwise often result in suffering, poor outcomes, in the worst cases premature death, and also high costs,” he says.
“In terms of time, organs can also be shipped longer distances, thus making more organs available for transplantation. It is also likely that we can start using less ideal organs from older donors, which could increase the number of heart transplants,” concludes Göran Dellgren.
Hypothermic oxygenated perfusion of the donor heart in heart transplantation; Short term outcome from a randomized, controlled, open label, multicenter clinical trial (NIHP2019)
Prof Filip Rega PhD, Prof Guillaume Lebreton PhD, Marylou Para MD, Prof Sebastian Michel PhD, Prof René Schramm PhD, Emmanuelle Begot MD, Katrien Vandendriessche MD, Christine Kamla MD, Prof Gino Gerosa MD, Marius Berman MD, Prof Udo Boeken PhD, Prof Steven Clark PhD, Aaron Ranasinghe MD, Fabio Ius PhD, Alberta Forteza PhD, Aldina Pivodic PhD, Felix Hennig MD, Sabina Guenther MD, Andreas Zuckermann PhD, Prof Christoph Knosalla PhD, Prof Göran Dellgren PhD, Andreas Wallinder PhD
https://doi.org/10.1016/S0140-6736(24)01078-X
The Lancet
Attached files
  • The ‘Heart-in-a-box’ used in the study (photo: Jakob Lundberg/University of Gothenburg)
  • Prof. Göran Dellgren (photo: Jakob Lundberg/University of Gothenburg)
  • Andreas Wallinder MD/PhD (photo: Jakob Lundberg/University of Gothenburg)
Regions: Europe, Sweden
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
  • iesResearch
Copyright 2024 by AlphaGalileo Terms Of Use Privacy Statement